Consensus on early detection of disease progression in patients with multiple sclerosis
| العنوان: | Consensus on early detection of disease progression in patients with multiple sclerosis |
|---|---|
| المؤلفون: | Meca-Lallana, José E, Casanova, Bonaventura, Rodríguez-Antigüedad, Alfredo, Eichau, Sara, Izquierdo, Guillermo, Durán, Carmen, Río, Jordi, Hernández, Miguel Ángel, Calles, Carmen, Prieto-González, José M, Ara, José Ramón, Uría, Dionisio F, Costa-Frossard, Lucienne, García-Merino, Antonio, Oreja-Guevara, Celia |
| المساهمون: | Institut Català de la Salut, [Meca-Lallana JE] CSUR Multiple Sclerosis and Clinical Neuroimmunology Unit, Neurology Department, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain. [Casanova B] Department of Neurology, Hospital Universitario y Politécnico La Fe, Valencia, Spain. [Rodríguez-Antigüedad A] Department of Neurology, Hospital Universitario Cruces, Barakaldo, Spain. [Eichau S] Department of Neurology, Hospital Universitario Virgen Macarena, Sevilla, Spain. [Izquierdo G] Fundación DINAC, Sevilla, Spain. [Durán C] Department of Neurology, Hospital Universitario de Badajoz, Badajoz, Spain. [Río J] Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Frontiers in neurology r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname Scientia |
| بيانات النشر: | Frontiers Media SA, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | secondary progressive multiple sclerosis, Otros calificadores::/diagnóstico [Otros calificadores], Presa de decisions, Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis [DISEASES], multiple sclerosis, Esclerosi múltiple - Prognosi, Psychological Phenomena::Mental Processes::Thinking::Decision Making::Consensus [PSYCHIATRY AND PSYCHOLOGY], afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::progresión de la enfermedad [ENFERMEDADES], disease progression, Neurology, consensus, enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES], Esclerosi múltiple - Diagnòstic, Other subheadings::/diagnosis [Other subheadings], Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression [DISEASES], Neurology (clinical), fenómenos psicológicos::procesos mentales::pensamiento::toma de decisión::consenso [PSIQUIATRÍA Y PSICOLOGÍA], early detection |
| الوصف: | Consensus; Early detection; Secondary progressive multiple sclerosis Consenso; Detección precoz; Esclerosis múltiple progresiva secundaria Consens; Detecció precoç; Esclerosi múltiple progressiva secundària Background: Early identification of the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS) can be challenging for clinicians, as diagnostic criteria for SPMS are primarily based on physical disability and a holistic interpretation. Objective: To establish a consensus on patient monitoring to identify promptly disease progression and the most useful clinical and paraclinical variables for early identification of disease progression in MS. Methods: A RAND/UCLA Appropriateness Method was used to establish the level of agreement among a panel of 15 medical experts in MS. Eighty-three items were circulated to the experts for confidential rating of the grade of agreement and recommendation. Consensus was defined when ≥66% agreement or disagreement was achieved. Results: Consensus was reached in 72 out of 83 items (86.7%). The items addressed frequency of follow-up visits, definition of progression, identification of clinical, cognitive, and radiological assessments as variables of suspected or confirmed SPMS diagnosis, the need for more accurate assessment tools, and the use of promising molecular and imaging biomarkers to predict disease progression and/or diagnose SPMS. Conclusion: Consensus achieved on these topics could guide neurologists to identify earlier disease progression and to plan targeted clinical and therapeutic interventions during the earliest stages of SPMS. This work was supported by Novartis. Meetings, data analysis, and medical writing assistance were funded by Novartis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1664-2295 |
| DOI: | 10.3389/fneur.2022.931014 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::125b7597254ad2d2ee30ddb5a4961f86Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....125b7597254ad2d2ee30ddb5a4961f86 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16642295 |
|---|---|
| DOI: | 10.3389/fneur.2022.931014 |